Literature DB >> 28675230

One-pot synthesis of nanochain particles for targeting brain tumors.

V S Perera1, G Covarrubias, M Lorkowski, P Atukorale, A Rao, S Raghunathan, R Gopalakrishnan, B O Erokwu, Y Liu, D Dixit, S M Brady-Kalnay, D Wilson, C Flask, J Rich, P M Peiris, E Karathanasis.   

Abstract

To synthesize multi-component nanochains, we developed a simple 'one-pot' synthesis, which exhibited high yield and consistency. The nanochains particles consist of parent nanospheres chemically linked into a higher-order, chain-like assembly. The one-pot synthesis is based on the addition of two types of parent nanospheres in terms of their surface chemical functionality (e.g., decorated with PEG-NH2 or PEG-COOH). By reacting the two types of parent nanospheres at a specific ratio (∼2 : 1) for a short period of time (∼30 min) under rigorous stirring, nanochains were formed. For example, we show the synthesis of iron oxide nanochains with lengths of about 125 nm consisting of 3-5 constituting nanospheres. The chain-like shaped nanoparticle possessed a unique ability to target and rapidly deposit on the endothelium of glioma sites via vascular targeting. To target and image invasive brain tumors, we used iron oxide nanochains with the targeting ligand being the fibronectin-targeting peptide CREKA. Overexpression of fibronectin is strongly associated with the perivascular regions of glioblastoma multiforme and plays a critical role in migrating and invasive glioma cells. In mice with invasive glioma tumors, 3.7% of the injected CREKA-targeted nanochains was found in gliomas within 1 h. Notably, the intratumoral deposition of the nanochain was ∼2.6-fold higher than its spherical variant. Using MR imaging, the precise targeting of nanochains to gliomas provided images with the exact topology of the disease including their margin of infiltrating edges and distant invasive sites.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28675230      PMCID: PMC5557407          DOI: 10.1039/c7nr02370g

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  43 in total

Review 1.  Gliomas--past, present, and future.

Authors:  K L Black; B K Pikul
Journal:  Clin Neurosurg       Date:  1999

2.  Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Authors:  Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Attila Birò; Alessandra Dorcaratto; Giuseppe L Viale; Dario Neri; Luciano Zardi
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Biomimetic amplification of nanoparticle homing to tumors.

Authors:  Dmitri Simberg; Tasmia Duza; Ji Ho Park; Markus Essler; Jan Pilch; Lianglin Zhang; Austin M Derfus; Meng Yang; Robert M Hoffman; Sangeeta Bhatia; Michael J Sailor; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

4.  Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues.

Authors:  T Ohnishi; S Hiraga; S Izumoto; H Matsumura; Y Kanemura; N Arita; T Hayakawa
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

5.  MRI mediated, non-invasive tracking of intratumoral distribution of nanocarriers in rat glioma.

Authors:  Efstathios Karathanasis; Jaekeun Park; Abhiruchi Agarwal; Vijal Patel; Fuqiang Zhao; Ananth V Annapragada; Xiaoping Hu; Ravi V Bellamkonda
Journal:  Nanotechnology       Date:  2008-06-17       Impact factor: 3.874

6.  New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy.

Authors:  C Rousselle; P Clair; J M Lefauconnier; M Kaczorek; J M Scherrmann; J Temsamani
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

7.  Penetration of intra-arterially administered vincristine in experimental brain tumor.

Authors:  Frances M Boyle; Susan L Eller; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2004-10       Impact factor: 12.300

Review 8.  Crossing the barrier: treatment of brain tumors using nanochain particles.

Authors:  Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-09

9.  Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.

Authors:  Laura Borsi; Enrica Balza; Marco Bestagno; Patrizia Castellani; Barbara Carnemolla; Attila Biro; Alessandra Leprini; Jorge Sepulveda; Oscar Burrone; Dario Neri; Luciano Zardi
Journal:  Int J Cancer       Date:  2002-11-01       Impact factor: 7.396

Review 10.  Current data and strategy in glioblastoma multiforme.

Authors:  Gabriel Iacob; Eduard B Dinca
Journal:  J Med Life       Date:  2009 Oct-Dec
View more
  8 in total

1.  Precise targeting of cancer metastasis using multi-ligand nanoparticles incorporating four different ligands.

Authors:  P M Peiris; F He; G Covarrubias; S Raghunathan; O Turan; M Lorkowski; B Gnanasambandam; C Wu; W P Schiemann; E Karathanasis
Journal:  Nanoscale       Date:  2018-04-19       Impact factor: 7.790

2.  Quantitative analysis of metastatic breast cancer in mice using deep learning on cryo-image data.

Authors:  Yiqiao Liu; Madhusudhana Gargesha; Mohammed Qutaish; Zhuxian Zhou; Peter Qiao; Zheng-Rong Lu; David L Wilson
Journal:  Sci Rep       Date:  2021-09-01       Impact factor: 4.996

3.  Treatment of glioblastoma using multicomponent silica nanoparticles.

Authors:  O Turan; P A Bielecki; V Perera; M Lorkowski; G Covarrubias; K Tong; A Yun; Georgia Loutrianakis; S Raghunathan; Y Park; T Moon; S Cooley; D Dixit; M A Griswold; K B Ghaghada; P M Peiris; J N Rich; E Karathanasis
Journal:  Adv Ther (Weinh)       Date:  2019-09-04

4.  PTPmu-targeted nanoparticles label invasive pediatric and adult glioblastoma.

Authors:  Gil Covarrubias; Mette L Johansen; Jason Vincent; Bernadette O Erokwu; Sonya E L Craig; Abdelrahman Rahmy; Anthony Cha; Morgan Lorkowski; Christina MacAskill; Bryan Scott; Madhusudhana Gargesha; Debashish Roy; Chris A Flask; Efstathios Karathanasis; Susann M Brady-Kalnay
Journal:  Nanomedicine       Date:  2020-05-13       Impact factor: 5.307

5.  Effect of Dose and Selection of Two Different Ligands on the Deposition and Antitumor Efficacy of Targeted Nanoparticles in Brain Tumors.

Authors:  Oguz Turan; Peter Bielecki; Kathleen Tong; Gil Covarrubias; Taylor Moon; Abdelrahman Rahmy; Shane Cooley; Youngjun Park; Pubudu M Peiris; Ketan B Ghaghada; Efstathios Karathanasis
Journal:  Mol Pharm       Date:  2019-09-03       Impact factor: 5.364

6.  Hyperthermia-mediated changes in the tumor immune microenvironment using iron oxide nanoparticles.

Authors:  Gil Covarrubias; Morgan E Lorkowski; Haley M Sims; Georgia Loutrianakis; Abdelrahman Rahmy; Anthony Cha; Eric Abenojar; Sameera Wickramasinghe; Taylor J Moon; Anna Cristina S Samia; Efstathios Karathanasis
Journal:  Nanoscale Adv       Date:  2021-09-01

Review 7.  Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy.

Authors:  Morgan E Lorkowski; Prabhani U Atukorale; Ketan B Ghaghada; Efstathios Karathanasis
Journal:  Adv Healthc Mater       Date:  2020-11-23       Impact factor: 9.933

8.  Imaging breast cancer using a dual-ligand nanochain particle.

Authors:  Gil Covarrubias; Anthony Cha; Abdelrahman Rahmy; Morgan Lorkowski; Vindya Perera; Bernadette O Erokwu; Chris Flask; Pubudu M Peiris; William P Schiemann; Efstathios Karathanasis
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.